Introduction: L’expansion palatine du maxillaire a beaucoup d’effets positifs sur la respiration et la qualité du sommeil, mais peu d'études ont examiné ces données sur des adultes ayant dépassé l’âge permettant de bénéficier d'une expansion palatine conventionnelle. Le but de cette recherche est d’évaluer la stabilité de l’EPRAC (expansion palatine rapide assistée chirurgicalement) et son effet sur les troubles respiratoires après l’ablation des appareils orthodontiques. Méthodes: Neuf patients (Âge moyen 21, entre 16-39 ans) nécessitant une EPRAC ont passé des nuits dans un laboratoire de sommeil, et ce avant l’EPRAC, après l’EPRAC, et après l’ablation des appareils fixes. Les radiographies céphalométriques postéroantérieures ainsi que les modèles d’étude ont été pris pendant ces trois périodes de temps. Résultats: L’analyse des modèles d’étude a démontré une récidive significative au niveau des distances inter-molaires et inter-canines au niveau du maxillaire seulement. Les analyses céphalométriques ont démontré une récidive au niveau de la largeur maxillaire. Aucun changement important n'a été observé dans les stades de sommeil, mais une réduction importante dans l’index de ronflement a été notée. De plus, il y avait moins de changements entre les stades de sommeil. Conclusions: La récidive squelettique est minime et cliniquement non significative. Par contre, les changements dans les distances intermolaires et intercanines sont cliniquement importants. Il semble également qu'une EPRAC ait un effet positif sur la qualité de sommeil par la réduction de l’indice de ronflement ainsi que sur la diminution des changements entre les stades de sommeil. / Introduction: Orthopedic expansion appears to have several positive effects on respiration as well as sleep quality, but a lack of studies examine these findings using SARPE on skeletally mature individuals. The aim of this study was to evaluate post-SARPE stability as well as its effect on sleep disordered breathing after completing full fixed orthodontics. Methods: 9 patients (average age 21, range 16-39) requiring SARPE underwent polysomnographic testing in sleep laboratory before SARPE (T0), after SARPE (T1), and after removal of full fixed appliances (T2). Study models and anteroposterior cephalometric radiographs were also taken at the 3 time points. Results: Study model analysis showed significant relapse for intermolar and intercanine widths. Anteroposterior cephalometric results were significant only for effective maxillary width. There were no significant changes in any sleep stages, however a dramatic reduction in snoring as well as fewer stage shifts were observed. Conclusions: Although statistically significant relapse was observed on study models and anteroposterior cephalometric radiographs, the dental relapse appears to be more clinically significant than the skeletal relapse. SARPE appears to have a positive effect on sleep quality by reducing the snoring index as well as reducing transitions between sleep stages.

INTRODUÇÃO: A apnéia obstrutiva do sono (AOS) é caracterizada como uma doença crônica, progressiva, incapacitante, com alta morbidade e mortalidade cardiovascular, sendo causada pela obstrução dinâmica repetitiva da via aérea superior (VAS). As repercussões geram necessidade de tratamento. Dentre os tratamentos disponíveis e com efetividade comprovada, há a opção de uso dos aparelhos intraorais. Neste estudo, avaliou-se a eficácia de um tipo de aparelho intraoral (AIO) monobloco, assim como suas complicações e intercorrências em longo prazo, em hospital de ensino. MÉTODOS: 20 pacientes participaram do presente estudo. Foram incluídos pacientes com diagnóstico polissonográfico prévio de AOS leve ou moderada (5 >IAH< 30), com idade até 60 anos, e não obesos. O critério de exclusão foi para pacientes em uso de medicamentos psicotrópicos, não condição oral para suporte do AIO e IMC e idade acima do proposto. Após 60 dias de uso do AIO realizou-se nova polissonografia (PSG), e acompanhamento pelo questionário RDC/TMD e ficha clínica EDOF/HC basal, 60 e 180 dias. RESULTADOS: Dentre os 20 pacientes, 11 eram do sexo masculino e nove do sexo feminino, com média de idade de 51 anos, e a média do IMC foi de 27,76. O índice de apnéia e hipopnéia (IAH) apresentou decréscimo de 19,23 para 7,51 eventos/hora de sono (p= 0,001). O eixo I e II do RDC/TMD não apresentou alterações significativas nos três momentos avaliados, porém o eixo II mostrou que os pacientes desta amostra apresentam maior grau de sintomas físicos e depressivos do que o padrão. CONCLUSÕES: No período estudado houve redução significativa do índice de apnéia e hipopnéia com o uso do aparelho intra-oral monobloco e foi eficaz total ou parcialmente no tratamento de 80% dos pacientes. As complicações não foram homogêneas e mostraram-se transitórias. / INTRODUCTION: Obstructive sleep apnea (OSA) is characterized as a chronic, progressive, disabling condition with high cardiovascular morbidity and mortality, and with repetitive episodes of upper airway (UA) obstruction. Its impact generates need for treatment. Among the treatments available and with demonstrated effectiveness, there is the option of using the oral appliances. In this study, we evaluated the effectiveness of a type of monoblock oral appliance (OA), as well as its complications and long-term complications in teaching hospital. METHODS: 20 patients participated in this study. We included patients with polysomnographic diagnosis of OSA prior mild or moderate (5> AHI <30), aged up to 60 years and not obese. The exclusion criteria were patients using psychotropic drugs, not oral condition to support the AIO and BMI and age above proposed. After 60 days of use of OA underwent a polysomnography (PSG) exam and follow-up by clinical record EDOF/HC and questionnaire RDC/TMD at baseline, 60 and 180 days. RESULTS: 11 male and nine female, mean age 51 years, and mean BMI was 27.76. The apnea-hypopnea index (AHI) showed a decrease of 19.23 to 7.51 events/hour of sleep (p = 0.001). Axis I and II of the RDC / TMD was not significantly changed in the three moments, but the axis II showed that patients in this sample have a higher degree of physical symptoms and depression than the standard. CONCLUSIONS: Oral appliance therapy for obstructive sleep apnea over the period reduced significantly the AHI and was totally or partially effective in treating 80% of patients. Complications were not homogeneous and were transient.

O ronco é gerado pela obstrução parcial e vibração da faringe durante o sono. Apesar de causar graves problemas sociais e poder indicar presença de apneia obstrutiva do sono (AOS), o ronco não é medido de forma objetiva. O tratamento do ronco primário ou associado a formas leves de AOS é controverso. A Terapia Miofuncional Orofacial consiste em exercícios isotônicos e isométricos para língua e palato mole desenvolvidos para o tratamento da AOS moderada. No entanto, os efeitos da Terapia Miofuncional Orofacial sobre o ronco não foram medidos de forma objetiva. OBJETIVOS: Primário: determinar a eficiência da Terapia Miofuncional Orofacial em reduzir o ronco de pacientes com ronco primário, AOS leve e moderada. Secundários: desenvolver uma metodologia de quantificação objetiva do ronco; avaliar a relação das características do ronco com a gravidade da AOS; avaliar o efeito da terapia miofuncional orofacial sobre a percepção do ronco e sobre a qualidade de sono do parceiro de quarto. MÉTODOS: Foram incluídos pacientes de ambos os sexos, com idade entre 20 e 65 anos com diagnóstico polissonográfico de ronco primário, AOS leve ou AOS moderada. Os pacientes foram randomizados por 3 meses para tratamento com Terapia Miofuncional Orofacial ou Controle (uso de dilatador nasal e exercícios respiratórios). Os pacientes foram avaliados no início e final do estudo por questionários de grau de sonolência (Epworth), qualidade de sono (Pittsburgh), percepção do próprio ronco e avaliação de motricidade orofacial, bem como polissonografia completa com registro contínuo do ronco. Os parceiros de quarto avaliaram o ronco do parceiro incluído no estudo e a sua própria qualidade do sono (Pittsburgh). RESULTADOS: Foram incluídos 39 pacientes com idade (média ± desvio padrão) = 46 ± 13 anos e índice de massa corpórea (IMC) = 28,2 ± 3,1 Kg/m2, Índice de apneia e hipopneia (IAH) = 15,3 ± 9,3 eventos/hora, sendo 6 pacientes com ronco primário, 17 com AOS leve e 16 com AOS moderada. Os pacientes não tiveram mudança de IMC, sendo que no Grupo Controle todos os parâmetros avaliados não se modificaram significativamente. Em contraste, os pacientes tratados com Terapia Miofuncional Orofacial apresentaram, em relação ao basal, melhora significativa (p < 0.05) na circunferência cervical ( 38,0 [36,4-39,5] vs. 37,5 [36,0-39,0] cm), na avaliação miofuncional orofacial (37,0 [23,0-42,0] vs. 19 [13,0-24,0]), no Índice de Roncos (99,5 [49,6-221,3] vs. 48,2 [25,5-219,2]) e no Índice Potência Total dos Roncos. (60,4 [21,8-220,6] vs. 31,0 [10,1-146,5]). Os parceiros de quarto dos pacientes tratados com terapia miofuncional orofacial (n=13), relataram melhora significativa na percepção da intensidade (4,0 [2,5-4,0]) vs. 1,0 [1,0-2,0]) e frequência do ronco (4,0 [3,0-4,0] vs. 2,0 [1,5-3,0]). A melhora da qualidade de sono dos parceiros de quarto dos pacientes tratados com Terapia Miofuncional Orofacial tiveram uma tendência a melhorar, porém não atingiu significância estatística (p=0,0618). O Índice de Ronco e o Índice Potência total do Ronco no basal e após 3 meses apresentaram uma correlação moderada com a gravidade da AOS, mensurada pelo IAH (r variando entre 0,505 a 0,603). CONCLUSÕES: A Terapia Miofuncional Orofacial por 3 meses foi efetiva em reduzir a frequência e intensidade do ronco, mensurados objetivamente. A Terapia Miofuncional Orofacial portanto pode ser efetiva para uma grande parcela da população que apresenta ronco primário ou formas leves de AOS / Snoring is generated by pharyngeal obstruction and vibration during sleep. Snoring is extremely common and may cause severe social problems and may indicate obstructive sleep apnea (OSA). However, there are no standardized methods for measuring snoring and the treatment of primary snoring or snoring associated with mild forms of OSA is controversial. Orofacial Myofunctional Therapy consists of isometric and isotonic exercises directed to tongue and soft palate for the treatment of moderated OSA. However, the effects of Orofacial Myofunctional Therapy on snoring were not objectively measured. OBJECTIVES: Primary: to determine the efficiency of Orofacial Myofunctional Therapy in reducing snoring of patients with primary snoring, mild and moderated OSA. Secondary: to develop a methodology to objectively quantify snoring; to assess the relation of snoring characteristics with OSA severity; to assess the effect of Orofacial Myofunctional Therapy upon the perception of snoring and sleep quality of the bed partner. METHODS: We included patients of both genders aged between 20 to 65 years old with polissomnographyc diagnoses of primary snoring, mild or moderated OSA. Patients were randomized for treatment with Orofacial Myofunctional Therapy or Control (use of nasal dilator strips and respiratory exercises) for 3 months. All patients were evaluated at the beginning and end of the study by questionnaires (Epworth, Pittsburgh), orofacial motricity assessment and complete polysomnography with the register of snoring. Bed partners assessed snoring and their own sleep quality (Pittsburgh). RESULTS: Thirty nine patients aged (mean ± standard deviation) =46 ± 13 yeas old and body mass index (BMI) (mean ± standard deviation) = 28,2 ± 3,1 Kg/m2, apnea hypopnea index (AHI)= 15,3 ± 9,3 events/hour, being 6 patients with primary snoring, 17 with mild OSA and 16 with moderated OSA completed the study. No significant change occurred in the Control Group in all variables. In contrast, patients treated with Orofacial Myofunctional Therapy presented (as compared to baseline) a significant decrease (p < 0.05) in neck circumference (38,0 [36,4-39,5] vs. 37,5 [36,0-39,0] cm), Orofacial Motricity Assessment (37,0 [23,0-42,0] vs. 19 [13,0-24,0]), Snoring Index (99,5 [49,6-221,3] vs. 48,2 [25,5-219,2]) and Total Snoring (60,4 [21,8-220,6] vs. 31,0 [10,1-146,5]). Bed partners of patients treated with Orofacial Myofunctional Therapy (n=13) reported a significant improvement in the perceived intensity (4,0 [2,5-4,0]) vs. 1,0 [1,0-2,0]) and snoring frequency (4,0 [3,0-4,0] vs. 2,0 [1,5-3,0]). Sleep quality of bed partners also improved but did not reach statistical significance (p=0.0618). Snoring Index and Total Snoring at basal and after 3 months presented a moderated correlation to OSA severity, measured by AHI (r between 0,505 to 0,603). CONCLUSIONS: Orofacial Myofunctional Therapy for 3 months is effective in reducing objectively measured snoring frequency and intensity. Orofacial Myofunctional Therapy can be effective for a great number of the population who present primary snoring or mild OSA forms

O avançar da idade é reconhecidamente um fator de risco para a Síndrome da Apneia Obstrutiva do Sono (SAOS). O motivo dessa constatação está associado à diminuição do tônus da musculatura orofaringeana e à redução da Dimensão Vertical de Oclusão (DVO), esta última atribuída às perdas dentárias. A abordagem odontológica, no tratamento da SAOS, refere-se ao uso de Aparelho de Avanço Mandibular (AAM), que impede a obstrução, parcial ou total, da passagem do ar pela via respiratória alta, durante o sono. Os pacientes desdentados, no entanto, têm sido negligenciados, nos estudos atualmente realizados. Pelo exposto, este trabalho objetivou avaliar os efeitos do tratamento em variáveis polissonográficas, ronco, sonolência, qualidade do sono e ainda os efeitos colaterais pelo uso do AAM titulável, em pacientes idosos e desdentados portadadores de SAOS. A metodologia envolveu inicialmente, cinquenta pacientes, dos quais dezesseis realizaram polissonografia de noite inteira, com gravação do ronco, por meio de um Roncômetro, visando investigação objetiva do sono. Analisaram-se subjetivamente frequência e intensidade do ronco, por questionários. A Escala Visual Analógica de Ronco (EVAR), aplicada ao parceiro de quarto, permitiu, igualmente, que fosse avaliada a intensidade desse sintoma. A sonolência diurna foi quantificada pela Escala de Sonolência de Epworth e a qualidade do sono, pelo Índice de Qualidade do Sono de Pittsburgh. Confecção individualizada dos AAMs respeitou os princípios biológicos relativos à DVO. Durante uma semana após a instalação, os pacientes utilizavam o AMM sem qualquer avanço mandibular, visando redução de quaisquer desconfortos. Subsequentemente, o protocolo estabelecia titulação gradual e progressiva (30%, 50% e 70%) do aparelho. Transposta a etapa de adaptação, após um período superior a quinze dias, as avaliações iniciais foram repetidas Os efeitos colaterais pelo uso do AAM e adesão ao tratamento foram investigados, a partir de questionários. Doze pacientes completaram o estudo (83,3% mulheres), sendo a media de idade 68 anos e índice de massa corporal médio de 28,3 kg/m2. Os resultados permitiram observar reduções significantes no índice de dessaturação de O2 (17,710,1 eventos/h, p=0,05) e índice de apneia (3,10,9 eventos/h, p=0,02). O uso do AAM evidenciou também diminuições na latência do sono REM, movimentos períodicos de perna, saturação mínima de O2, índice de apneia e hipopneia, na posição supina (p>0,05). O estudo objetivo do ronco apontou redução de 49,522,6 eventos/h (p=0,07). Além do mais, as avaliações subjetivas de frequência (p=0,024) e intensidade (p=0,007) do ronco, EVAR (p=0,003), qualidade do sono (p=0,008), efeitos colaterais e adesão ao AAM foram estatisticamente significantes. Foi possível concluir pela eficácia do tratamento sobre algumas variáveis polissonográficas estudadas, parâmetros subjetivos do ronco e qualidade do sono. Ademais, os sintomas relatados, pelo uso do AAM, reduziram-se ao longo do tempo, o que permitiu, com vantagem, que houvesse maior adesão ao tratamento por parte dos pacientes inseridos nesta pesquisa. / Aging process is well known as a risky factor to Obstructive Sleep Apnea Syndrome (OSAS). Concomitant with this process, the reduction of orofacial and pharyngeal musculature tone, as well as the decrease of Vertical Occlusion Dimension (VOD), the latter attributed to tooth loss, have been considered as probable causal agents involved in OSAS pathogenesis. The Dentistry approach for OSAS treatment is commonly related to the use of Mandibular Advancement Devices (MAD), which could prevent partial or complete upper airway obstruction during sleep. However, this treatment has been scarcely used in toothless patients. The aim of this study was to assess the effects of a titratable MAD in polysomnographic (PSG) variables, snoring, sleepiness, sleep quality and side effects, in edentulous elderly patients with OSAS. Sixteen out of fifty patients assessed have been selected and have undergone an overnight polysomnographic study. Snoring was recorded by using suitable equipment, so that an objective assessment of sleep patterns could be made. The frequency and intensity of snoring have also been subjectively assessed by means of questionnaires. The Snoring Visual Analogic Scale (SVAS), posed to a bed partner, was also assessed to evaluate snoring intensity. Excessive daytime sleepiness and the quality of sleep have also been investigated by Epworth Sleepiness Scale and Pittsburgh Sleep Quality Index, respectively. The patients went through the whole process for individually manufacturing of the MAD following the biological principles of the VDO. A week after using the MAD, at 0% of mandibular advancement, the patients were invited to return in order to undergo a new evaluation according to their adaptation to MAD. Subsequently, a titration protocol was gradually established at 30%, 50% and 70% for mandibular advancement. After a period of at least fifteen days, which should correspond to an adjustment of patients to their devices, the same initial assessment procedures were repeated. The MAD collateral effects as well as the treatment acceptance have been investigated through questionnaires. Twelve patients (83,3% females) completed the study, with an average age of 68 years, body mass index of 28,3 kg/m2. The results showed a significant reduction in O2 desaturation index (17,710,1 event/h, p=0,05) and also in AI (3,10,9 events/h, p=0,02). The use of the MAD also represented reductions in the latency to REM sleep, periodical leg movements, minimum O2 saturation, apnea and hypopnea index (AHI) in supine position (p>0,05). The objective assessment of snoring showed a reduction, with no statistical relevance of the Snoring Index (49,522,6 events per hour of recording, p=0,07). The subjective assessment of frequency (p=0,024) and intensity of snoring (p=0,007), EVAR (p=0,003), sleep quality (p=0,008) and the MAD collateral effects as well as the treatment acceptance were also statistically significant. We observed that the OSAS treatment with MAD was effective in some polysomnografic variables studied as well as in the subjective parameters of snoring and sleep quality in edentulous elderly patients. The reported symptoms due to MAD use decreased over the time.

O ronco é gerado pela obstrução parcial e vibração da faringe durante o sono. Apesar de causar graves problemas sociais e poder indicar presença de apneia obstrutiva do sono (AOS), o ronco não é medido de forma objetiva. O tratamento do ronco primário ou associado a formas leves de AOS é controverso. A Terapia Miofuncional Orofacial consiste em exercícios isotônicos e isométricos para língua e palato mole desenvolvidos para o tratamento da AOS moderada. No entanto, os efeitos da Terapia Miofuncional Orofacial sobre o ronco não foram medidos de forma objetiva. OBJETIVOS: Primário: determinar a eficiência da Terapia Miofuncional Orofacial em reduzir o ronco de pacientes com ronco primário, AOS leve e moderada. Secundários: desenvolver uma metodologia de quantificação objetiva do ronco; avaliar a relação das características do ronco com a gravidade da AOS; avaliar o efeito da terapia miofuncional orofacial sobre a percepção do ronco e sobre a qualidade de sono do parceiro de quarto. MÉTODOS: Foram incluídos pacientes de ambos os sexos, com idade entre 20 e 65 anos com diagnóstico polissonográfico de ronco primário, AOS leve ou AOS moderada. Os pacientes foram randomizados por 3 meses para tratamento com Terapia Miofuncional Orofacial ou Controle (uso de dilatador nasal e exercícios respiratórios). Os pacientes foram avaliados no início e final do estudo por questionários de grau de sonolência (Epworth), qualidade de sono (Pittsburgh), percepção do próprio ronco e avaliação de motricidade orofacial, bem como polissonografia completa com registro contínuo do ronco. Os parceiros de quarto avaliaram o ronco do parceiro incluído no estudo e a sua própria qualidade do sono (Pittsburgh). RESULTADOS: Foram incluídos 39 pacientes com idade (média ± desvio padrão) = 46 ± 13 anos e índice de massa corpórea (IMC) = 28,2 ± 3,1 Kg/m2, Índice de apneia e hipopneia (IAH) = 15,3 ± 9,3 eventos/hora, sendo 6 pacientes com ronco primário, 17 com AOS leve e 16 com AOS moderada. Os pacientes não tiveram mudança de IMC, sendo que no Grupo Controle todos os parâmetros avaliados não se modificaram significativamente. Em contraste, os pacientes tratados com Terapia Miofuncional Orofacial apresentaram, em relação ao basal, melhora significativa (p < 0.05) na circunferência cervical ( 38,0 [36,4-39,5] vs. 37,5 [36,0-39,0] cm), na avaliação miofuncional orofacial (37,0 [23,0-42,0] vs. 19 [13,0-24,0]), no Índice de Roncos (99,5 [49,6-221,3] vs. 48,2 [25,5-219,2]) e no Índice Potência Total dos Roncos. (60,4 [21,8-220,6] vs. 31,0 [10,1-146,5]). Os parceiros de quarto dos pacientes tratados com terapia miofuncional orofacial (n=13), relataram melhora significativa na percepção da intensidade (4,0 [2,5-4,0]) vs. 1,0 [1,0-2,0]) e frequência do ronco (4,0 [3,0-4,0] vs. 2,0 [1,5-3,0]). A melhora da qualidade de sono dos parceiros de quarto dos pacientes tratados com Terapia Miofuncional Orofacial tiveram uma tendência a melhorar, porém não atingiu significância estatística (p=0,0618). O Índice de Ronco e o Índice Potência total do Ronco no basal e após 3 meses apresentaram uma correlação moderada com a gravidade da AOS, mensurada pelo IAH (r variando entre 0,505 a 0,603). CONCLUSÕES: A Terapia Miofuncional Orofacial por 3 meses foi efetiva em reduzir a frequência e intensidade do ronco, mensurados objetivamente. A Terapia Miofuncional Orofacial portanto pode ser efetiva para uma grande parcela da população que apresenta ronco primário ou formas leves de AOS / Snoring is generated by pharyngeal obstruction and vibration during sleep. Snoring is extremely common and may cause severe social problems and may indicate obstructive sleep apnea (OSA). However, there are no standardized methods for measuring snoring and the treatment of primary snoring or snoring associated with mild forms of OSA is controversial. Orofacial Myofunctional Therapy consists of isometric and isotonic exercises directed to tongue and soft palate for the treatment of moderated OSA. However, the effects of Orofacial Myofunctional Therapy on snoring were not objectively measured. OBJECTIVES: Primary: to determine the efficiency of Orofacial Myofunctional Therapy in reducing snoring of patients with primary snoring, mild and moderated OSA. Secondary: to develop a methodology to objectively quantify snoring; to assess the relation of snoring characteristics with OSA severity; to assess the effect of Orofacial Myofunctional Therapy upon the perception of snoring and sleep quality of the bed partner. METHODS: We included patients of both genders aged between 20 to 65 years old with polissomnographyc diagnoses of primary snoring, mild or moderated OSA. Patients were randomized for treatment with Orofacial Myofunctional Therapy or Control (use of nasal dilator strips and respiratory exercises) for 3 months. All patients were evaluated at the beginning and end of the study by questionnaires (Epworth, Pittsburgh), orofacial motricity assessment and complete polysomnography with the register of snoring. Bed partners assessed snoring and their own sleep quality (Pittsburgh). RESULTS: Thirty nine patients aged (mean ± standard deviation) =46 ± 13 yeas old and body mass index (BMI) (mean ± standard deviation) = 28,2 ± 3,1 Kg/m2, apnea hypopnea index (AHI)= 15,3 ± 9,3 events/hour, being 6 patients with primary snoring, 17 with mild OSA and 16 with moderated OSA completed the study. No significant change occurred in the Control Group in all variables. In contrast, patients treated with Orofacial Myofunctional Therapy presented (as compared to baseline) a significant decrease (p < 0.05) in neck circumference (38,0 [36,4-39,5] vs. 37,5 [36,0-39,0] cm), Orofacial Motricity Assessment (37,0 [23,0-42,0] vs. 19 [13,0-24,0]), Snoring Index (99,5 [49,6-221,3] vs. 48,2 [25,5-219,2]) and Total Snoring (60,4 [21,8-220,6] vs. 31,0 [10,1-146,5]). Bed partners of patients treated with Orofacial Myofunctional Therapy (n=13) reported a significant improvement in the perceived intensity (4,0 [2,5-4,0]) vs. 1,0 [1,0-2,0]) and snoring frequency (4,0 [3,0-4,0] vs. 2,0 [1,5-3,0]). Sleep quality of bed partners also improved but did not reach statistical significance (p=0.0618). Snoring Index and Total Snoring at basal and after 3 months presented a moderated correlation to OSA severity, measured by AHI (r between 0,505 to 0,603). CONCLUSIONS: Orofacial Myofunctional Therapy for 3 months is effective in reducing objectively measured snoring frequency and intensity. Orofacial Myofunctional Therapy can be effective for a great number of the population who present primary snoring or mild OSA forms

<p>Obstructive sleep apnea (OSA) appears to affect up to 5% of the population. The extent to what pulmonary function awake and during sleep relates to obstructive breathing and hypoxemia during sleep in these patients is unclear. The aim of this study was to investigate respiratory function in patients with varying degree of snoring and OSA and to analyse regional lung aeration during sleep.</p><p>In all, 35 healthy subjects and 90 patients with snoring and OSA were studied. The ventilatory response to CO₂ (VRCO₂) was measured. Lung function tests were performed. A technique based on computed tomography was developed to study lung aeration during sleep.</p><p>Patients with OSA displayed a higher VRCO₂ in comparison to healthy subjects and snorers (p<0.01). Increased closing volume and reduced expiratory reserve volume (ERV) were found in patients with OSA (p<0.001). In a multiple regression analysis, ERV was an independent predictor of nocturnal apnea (R²=0.13; p=0.001) and desaturation frequency (R²=0.11; p<0.01). In both healthy subjects and OSA patients, lung aeration was reduced during sleep by 0.10 ml gas/g tissue in the dorsal lung region (p<0.05 and p<0.01). OSA patients had a significantly lower gas/tissue ratio in comparison to healthy subjects both awake (-23%; p<0.04) and during sleep (-25%; p<0.04). In a univariate analysis, functional residual capacity (FRC) correlated with the change in lung aeration from wakefulness to sleep (r=-0.78; p<0.001). In patients with OSA, ERV (r=-0.69; p<0.05) and sleep time (r=0.69; p<0.05) correlated with the fall in lung aeration. </p><p>In conclusion, patients with OSA display an increased ventilatory response to CO₂, reduced ERV and increased closing volume. ERV predicts nocturnal apnea and desaturation frequency to a similar extent as obesity. Lung aeration is reduced in the dorsal region during sleep and patients with OSA display a lower amount of gas in comparison to healthy subjects. Decrease in lung volumes, promoting airway closure, and loss of muscle tone contributed to the altered lung function during sleep.</p>

<p>The overall aims of our studies were to identify risk factors for respiratory symptoms and asthma in indoor environment but even to look at some personal risk factors such as body mass index and gastroesophageal reflux. The study population is based on participants of the European Community Respiratory Health Survey I and II. </p><p> In the first study, water damage and visible moulds were reported in 7.4% and 17% of the homes respectively. The combination of water damage and visible moulds was independently associated with attacks of breathlessness when resting and after activity and also to long term cough. In the second study, the prevalence of nocturnal GER increased with higher BMI and the same pattern could be seen for habitual snoring. Reported onset of asthma, wheeze and night-time symptoms increased in prevalence along with the BMI gradient. In the multivariable analysis, obesity and nocturnal GER were independent risk factors for onset of asthma, wheeze and night-time symptoms. Habitual snoring was an independent risk factor for onset of wheeze and night-time symptoms, but not for onset of asthma. In the third study, a total of 18% of the subjects reported indoor dampness in the last 12 months and 27% of the subjects reported indoor dampness since the previous survey. Respiratory symptoms and asthma were significantly more prevalent in individuals exposed to indoor dampness and indoor dampness was a risk factor for respiratory symptoms and asthma after adjusting for possible confounders. Indoor dampness was an independent risk factor for onset of respiratory symptoms but not for asthma onset. Remission of respiratory symptoms was less likely to occur if subjects reported indoor dampness. In the fourth study, the lowest prevalence of atopy and the lowest levels of all indoor allergens, bacteria and moulds were found in Iceland. A positive association was found, between cat allergen exposure and asthma symptoms and between bronchial hyperresponsiveness and the amount of viable mould in indoor air.</p>

Obstructive sleep apnea (OSA) appears to affect up to 5% of the population. The extent to what pulmonary function awake and during sleep relates to obstructive breathing and hypoxemia during sleep in these patients is unclear. The aim of this study was to investigate respiratory function in patients with varying degree of snoring and OSA and to analyse regional lung aeration during sleep. In all, 35 healthy subjects and 90 patients with snoring and OSA were studied. The ventilatory response to CO2 (VRCO2) was measured. Lung function tests were performed. A technique based on computed tomography was developed to study lung aeration during sleep. Patients with OSA displayed a higher VRCO2 in comparison to healthy subjects and snorers (p&lt;0.01). Increased closing volume and reduced expiratory reserve volume (ERV) were found in patients with OSA (p&lt;0.001). In a multiple regression analysis, ERV was an independent predictor of nocturnal apnea (R2=0.13; p=0.001) and desaturation frequency (R2=0.11; p&lt;0.01). In both healthy subjects and OSA patients, lung aeration was reduced during sleep by 0.10 ml gas/g tissue in the dorsal lung region (p&lt;0.05 and p&lt;0.01). OSA patients had a significantly lower gas/tissue ratio in comparison to healthy subjects both awake (-23%; p&lt;0.04) and during sleep (-25%; p&lt;0.04). In a univariate analysis, functional residual capacity (FRC) correlated with the change in lung aeration from wakefulness to sleep (r=-0.78; p&lt;0.001). In patients with OSA, ERV (r=-0.69; p&lt;0.05) and sleep time (r=0.69; p&lt;0.05) correlated with the fall in lung aeration. In conclusion, patients with OSA display an increased ventilatory response to CO2, reduced ERV and increased closing volume. ERV predicts nocturnal apnea and desaturation frequency to a similar extent as obesity. Lung aeration is reduced in the dorsal region during sleep and patients with OSA display a lower amount of gas in comparison to healthy subjects. Decrease in lung volumes, promoting airway closure, and loss of muscle tone contributed to the altered lung function during sleep.

The overall aims of our studies were to identify risk factors for respiratory symptoms and asthma in indoor environment but even to look at some personal risk factors such as body mass index and gastroesophageal reflux. The study population is based on participants of the European Community Respiratory Health Survey I and II. In the first study, water damage and visible moulds were reported in 7.4% and 17% of the homes respectively. The combination of water damage and visible moulds was independently associated with attacks of breathlessness when resting and after activity and also to long term cough. In the second study, the prevalence of nocturnal GER increased with higher BMI and the same pattern could be seen for habitual snoring. Reported onset of asthma, wheeze and night-time symptoms increased in prevalence along with the BMI gradient. In the multivariable analysis, obesity and nocturnal GER were independent risk factors for onset of asthma, wheeze and night-time symptoms. Habitual snoring was an independent risk factor for onset of wheeze and night-time symptoms, but not for onset of asthma. In the third study, a total of 18% of the subjects reported indoor dampness in the last 12 months and 27% of the subjects reported indoor dampness since the previous survey. Respiratory symptoms and asthma were significantly more prevalent in individuals exposed to indoor dampness and indoor dampness was a risk factor for respiratory symptoms and asthma after adjusting for possible confounders. Indoor dampness was an independent risk factor for onset of respiratory symptoms but not for asthma onset. Remission of respiratory symptoms was less likely to occur if subjects reported indoor dampness. In the fourth study, the lowest prevalence of atopy and the lowest levels of all indoor allergens, bacteria and moulds were found in Iceland. A positive association was found, between cat allergen exposure and asthma symptoms and between bronchial hyperresponsiveness and the amount of viable mould in indoor air.

Introduction: Les troubles respiratoires du sommeil (TRS), qui représentent une préoccupation croissante pour la santé, ont des effets significatifs sur la santé, le comportement et la performance académique chez l’enfant. Les malformations craniofaciales, l’hypertrophie adéno-amygdalienne et l'obésité, représentent des facteurs de risque importants dans le développement de cette condition. Les symptômes des TRS ont été étudiés dans une étude prospective chez les enfants et adolescents durant leur traitement orthodontique dans un milieu universitaire. Cette étude a cherché à décrire la prévalence et les facteurs de risque principaux des TRS, ainsi que l'impact des différentes interventions orthodontiques sur les symptômes TRS. Matériel et méthodes: dans une étude cohorte prospective, un groupe de 168 sujets âgés de 12 à 21 ans ont été soumis, quatre ans après la prise de données initiale, à un examen craniofacial en plus d'être administré des questionnaires qui ont recueilli des données sur la situation socio-démographique, le bruxisme et les troubles d’ATM, le sommeil et le comportement diurne, et les facteurs neuropsychologiques. Résultats: l'indice de masse corporelle a été augmenté mais est demeurée dans la même catégorie aux deux moments de l'enquête. Il ya eu une augmentation du serrement des dents et des symptômes de l'ATM, une diminution de la taille des amygdales, et une augmentation de la somnolence diurne. La prévalence des TRS n'a pas changé entre l’étude initiale et l’étude de suivi. Aucune intervention orthodontique s'est avérée avoir un effet cliniquement significatif sur les voies aériennes supérieures. Conclusions: la prévalence des symptômes TRS était constante par rapport aux valeurs de base pour la population étudiée, mais a augmenté si rapportée à la population générale. Les traitements orthodontiques ne montrent aucun effet sur les TRS. Mots-clés : apnée du sommeil, craniofacial, prévalence, ronflement, traitement orthodontique, voies aériennes supérieures / Introduction: Sleep-disordered breathing (SDB), a growing health concern, has significant effects on a child’s health, behaviour, and scholastic performance. Craniofacial malformations, along with adenotonsillar hypertrophy and obesity, represent important risk factors in the development of this condition. SDB symptoms in children and adolescents followed for orthodontic treatment in a university setting have been investigated in this prospective study. The aims of this study were to describe the prevalence and main risk factors of SDB and the impact of different orthodontic interventions on the SDB symptoms. Materials and methods: in a prospective cohort study, four years following an initial evaluation, a group of 168 subjects aged 12-21 years underwent a craniofacial examination in addition to being administered self-completed questionnaires that collected information on socio-demographic and psychosocial factors, bruxism and temporo-mandibular joint (TMJ) disorders, sleep and daytime behaviour, and neuropsychological factors. Results: Body mass index (BMI) was slightly increased but remained in the same category at the two time points of investigation. There was an increase in tooth clenching and TMJ symptoms, a decrease in tonsils’ size, and an increase in daytime sleepiness. Prevalence of SDB did not change between baseline and follow-up studies. No orthodontic treatment intervention proved to have any clinically significant impact on the upper airway. Conclusions: SDB symptoms prevalence was constant when compared to the baseline values for the studied population, but increased if reported to the general population. Regular orthodontic treatment didn’t show any effect on SDB symptoms. Keywords : craniofacial, orthodontic treatment, prevalence, sleep apnea, snoring, upper airway